DE69943020D1 - Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs - Google Patents

Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs

Info

Publication number
DE69943020D1
DE69943020D1 DE69943020T DE69943020T DE69943020D1 DE 69943020 D1 DE69943020 D1 DE 69943020D1 DE 69943020 T DE69943020 T DE 69943020T DE 69943020 T DE69943020 T DE 69943020T DE 69943020 D1 DE69943020 D1 DE 69943020D1
Authority
DE
Germany
Prior art keywords
tmprss2
prostate
diagnosis
therapy
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69943020T
Other languages
German (de)
English (en)
Inventor
Daniel E Afar
Rene S Hubert
Kahan Leong
Arthur B Raitano
Douglas C Saffran
Stephen Chappell Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of DE69943020D1 publication Critical patent/DE69943020D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69943020T 1998-06-01 1999-06-01 Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs Expired - Lifetime DE69943020D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8759898P 1998-06-01 1998-06-01
US9147498P 1998-06-29 1998-06-29
US12952199P 1999-04-14 1999-04-14
PCT/US1999/012253 WO1999062942A2 (en) 1998-06-01 1999-06-01 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer

Publications (1)

Publication Number Publication Date
DE69943020D1 true DE69943020D1 (de) 2011-01-20

Family

ID=27375711

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69943020T Expired - Lifetime DE69943020D1 (de) 1998-06-01 1999-06-01 Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs

Country Status (12)

Country Link
US (1) US20060275304A1 (enExample)
EP (1) EP1082341B1 (enExample)
JP (2) JP2002517185A (enExample)
AT (1) ATE490977T1 (enExample)
AU (2) AU773187B2 (enExample)
CA (1) CA2329137C (enExample)
CY (1) CY1111906T1 (enExample)
DE (1) DE69943020D1 (enExample)
DK (1) DK1082341T3 (enExample)
IL (1) IL139988A0 (enExample)
PT (1) PT1082341E (enExample)
WO (1) WO1999062942A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) * 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP1117794A2 (en) * 1998-10-02 2001-07-25 Urogenesys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
JP2002527758A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
EP1200590B1 (en) 1999-08-12 2009-01-07 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096538A2 (en) * 2000-06-13 2001-12-20 Bayer Aktiengesellschaft Regulation of human transmembrane serine protease
DE60138465D1 (de) * 2000-07-12 2009-06-04 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
US6743592B1 (en) * 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
WO2004097358A2 (en) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2008119767A2 (en) * 2007-03-30 2008-10-09 Oryzon Genomics, S. A. Method of nucleic acid analysis.
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
US9938582B2 (en) 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
KR102069397B1 (ko) * 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Ｆｃ-수용체 기재 친화성 크로마토그래피
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
AU675506B2 (en) * 1993-01-15 1997-02-06 Genetics Institute, Llc Cloning of enterokinase and method of use
US6657056B2 (en) * 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
EP1005546A2 (en) * 1997-02-25 2000-06-07 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2281954A1 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US20030103981A1 (en) * 1997-02-27 2003-06-05 Incyte Genomics, Inc. Methods of use of a prostate-associated protease in the diagnosis and treatment of prostate cancer
US20020119531A1 (en) * 1997-02-27 2002-08-29 Olga Bandman Prostate-associated protease antibody
US6043033A (en) * 1997-02-27 2000-03-28 Incyte Pharmaceuticals, Inc. Human prostate-associated protease
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
WO2000000605A1 (en) * 1998-06-29 2000-01-06 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US6331427B1 (en) * 1999-03-26 2001-12-18 Millennium Pharmaceuticals, Inc. Protease homologs
US20020192763A1 (en) * 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
US20030065157A1 (en) * 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer

Also Published As

Publication number Publication date
ATE490977T1 (de) 2010-12-15
IL139988A0 (en) 2002-02-10
AU773187B2 (en) 2004-05-20
EP1082341B1 (en) 2010-12-08
PT1082341E (pt) 2011-02-15
WO1999062942A2 (en) 1999-12-09
CA2329137C (en) 2011-09-20
JP2002517185A (ja) 2002-06-18
JP2009148265A (ja) 2009-07-09
EP1082341A2 (en) 2001-03-14
WO1999062942A3 (en) 2000-06-02
AU4413699A (en) 1999-12-20
AU2004202306B2 (en) 2007-05-24
DK1082341T3 (da) 2011-03-28
AU2004202306C1 (en) 2008-05-01
US20060275304A1 (en) 2006-12-07
CA2329137A1 (en) 1999-12-09
CY1111906T1 (el) 2015-11-04
AU2004202306A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
CY1111906T1 (el) Αντιγονο ογκων χρησιμο για τη διαγνωση και θεραπεια καρκινου του προστατη και του παχεος εντερου
Krüger et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
AU1726199A (en) Metastatic cancer regulated gene
ATE196315T1 (de) Interleukin-15
ATE11372T1 (de) Von vernetztem fibrin abgeleitete radiomarkierte peptide zur bestimmung von thrombi und die dieselben enthaltenden injektierbaren zusammensetzungen.
DE69528064D1 (de) Neuartige peptide
DE69839566D1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
ATE106943T1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
FI863188A0 (fi) Kombinationsfoerfaranden foer producering av serinproteas-inhibitorer och foer dessa anvaendbara dna-sekvenser.
US5698671A (en) Metalloproteinase peptides
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DK0922223T3 (da) Fremgangsmåde til prognosticering af cancer
CY1109254T1 (el) Νεο αντιγονο ογκου χρησιμο στη διαγνωση και θεραπεια καρκινων της ουροδοχου κυστης, των ωοθηκων, του πνευμονα και του νεφρου
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
Dardik et al. The structure of endothelial cell thrombospondin: Characterization of the heparin‐binding domains
NO991653D0 (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
WO1998045442A3 (en) Secreted f-spondin homologs
Durliat et al. Plasminogen receptors on rat colon carcinoma cells
DE60134956D1 (de) Gene differentiell experimiert in brudtkrebs
Pedersen et al. A non-catalytic, human urokinase plasminogen activator derivative produced by mouse cells has full receptor binding activity
AU2003222606A1 (en) Diagnosis of carcinoma using raigi polypeptides
ES8604692A1 (es) Metodo para la purificacion de enzima procoagulante, proteolitico a partir de extracto de tejido animal que contiene el enzima.